ICROVASCULAR extravasation is a common accompaniment of systemic and central nervous system (CNS) tumors. This process results in soft-tissue swelling, pulmonary edema, pleural effusions, ascites, peritumoral vasogenic brain edema (PVBE), and brain tumor-associated cysts (TACs). The latter two epiphenomena add considerably to brain tumor mass effect, contributing both to the local distortion of intracranial structures and a diffuse elevation of intracranial pressure. Biochemical factors such as histamines, serotonin, bradykinin, polyamines, leukokinins, prostaglandins, plasminogenic activators, and oxygen free radicals have all been implicated in the genesis of brain edema. 3, 5, 13, 24, 32 Although these substances have been shown to be potent inducers of microvascular permeability in association with allergic, ischemic, infectious, and inflammatory reactions, a convincing pathophysiological link between them and neoplastic brain edema has yet to be established.
Attention has now turned to a novel group of polypeptides that appear to mediate both angiogenesis and vascular extravasation. Vascular endothelial growth/permeability factor (VEG/PF) likely plays a pivotal role in normal vascular development (vasculogenesis), as well as in a great variety of pathological vascular responses (angiogenesis and microvascular extravasation). Vascular permeability factor (VPF) was first described in association with an ascites-producing guinea pig hepatocarcinoma. In 1983, Senger, et al., 38 identified g-VPF as a 34-to 42-kD basic protein with a marked affinity for heparin and a permeability-inducing ability three orders of magnitude greater than histamine. The first report of a human brain tumor VPF was made in 1987 when it was noted that conditioned medium derived from cultured human glial tumors contained a factor that induced cutaneous permeability in Miles assay. 4, 12, 33 Human glioma-derived VPF is a 41-to 56-kD heparin-binding protein with many simi-Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts larities to the g-VPF. Human glioma VPF exhibited similar potency to g-VPF, with permeability induction occurring with nanomolar amounts. Furthermore, preincubation of human glioma to a rabbit polyclonal immunoglobulin G (IgG) antibody raised against g-VPF resulted in neutralization of its permeability-inducing activity.
A variety of metastatic brain tumors have recently been shown to uniformly express the VEG/PF protein. Magnetic resonance (MR) imaging of these lesions using contrast medium revealed bright enhancement and extensive vasogenic edema. 40 A human VPF has now been isolated, purified, and sequenced from a histiocytic lymphoma cell line (U-937). The h-VPF molecule is a 38-to 40-kD, 189-amino acid cationic secretory homodimeric glycoprotein linked by disulfide bridges. Permeability induction in the Miles assay occurred at 1 nM. Notably, h-VPF appears to be a highly specific mitogen capable of inducing endothelial cell replication and migration essential to tumor angiogenesis. 6, 27 In vitro experiments using radiolabeled [
125 I]h-VPF have shown specific binding of this molecule to an endothelial cell-surface receptor. A specific receptor interaction has been further supported by the finding that vascular endothelial growth factor (VEGF), an endothelial cell mitogen nearly identical in sequence to VPF, binds to a transmembrane receptor of the tyrosine kinase family encoded by the flt-1 gene (the fms-like tyrosine kinase) that was identified by screening a human placental complementary (c)DNA library. 14 This investigation was undertaken to study patterns of VEG/PF protein expression in a series of low-grade and high-grade human gliomas to determine whether VEG/PF acts as a common pathophysiological link between two morphologically distinct epiphenomena of microvascular extravasation: PVBE and TAC formation. Although chosen sequentially, this series of glial neoplasms fully illustrates the spectrum of microvascular extravasation associated with gliomas. Specifically, we have studied benign and malignant tumors that demonstrated: 1) no evident microvascular extravasation (neither PVBE nor TAC), 2) PVBE, 3) TAC formation, and 4) vasogenic edema and cyst formation (both PVBE and TAC), in hope of further clarifying the role of VEG/PF in neoplastic vasogenic brain edema and TAC. Expression of VEG/PF protein was determined using a polyclonal IgG anti-VEG/PF immunostaining technique. Correlation was then made with respect to VEG/PF staining, the presence and extent of PVBE, the occurrence of fluid-filled tumor cysts, and tumor enhancement, using T 2 -weighted unenhanced and gadolinium-enhanced T 1 -weighted MR imaging.
Materials and Methods

Specimen Selection
Nineteen low-grade and 11 high-grade primary brain tumors were selected from a pool of paraffinized tumor specimens from patients who underwent surgery at Yale-New Haven Hospital in the preceding 2 years. To more accurately assess brain edema we included only tumors of the hemispheres and cerebellum, thus excluding intraventricular, suprasellar, brainstem, or spinal lesions. All specimens were immunostained with a perviously defined rabbit polyclonal anti-VEG/PF IgG antibody or preimmune rabbit serum IgG. Table 1 lists the tumor specimens according to  their neuropathological diagnosis and grading by World Health   Organization  29 criteria, presence and quantitation of PVBE,  VEG/PF expression, association with TAC, and the occurrence of  gadolinium enhancement. The tumors included 11 high-grade primary brain malignancies (four Grade III anaplastic astrocytomas,  seven Grade IV glioblastomas) and 19 low-grade tumors (13 Grade  I and II astrocytomas, two oligodendrogliomas, three gangliogliomas, one hamartoma). Four specimens of temporal lobe gliosis served as nonneoplastic controls. Results were further illustrated with representative MR images and immunostained photomicrographs of benign and malignant tumors that demonstrated 1) no evident microvascular extravasation (neither PVBE nor TAC), 2) only PVBE, 3) only TAC formation, or 4) both PVBE and TAC, in hope of further clarifying the role of VEG/PF in neoplastic vasogenic brain edema and TAC formation.
Estimation of Edema
All patients underwent preoperative MR imaging studies. Brain edema and TACs were demonstrated on T 2 -weighted, whereas tumor size was determined with gadolinium-enhanced T 1 -weighted images. Patients at Yale-New Haven Hospital undergoing MR imaging for tumor receive a standard dose of gadolinium depending on body weight (98.2 mg/kg). Tumor enhancement on MR imaging was assessed as either absent or present. An attempt was made to quantitate radiographically the degree of edema by referring to a method recently reported by Inamura, et al. 25 All MR images examined were preoperative studies that were usually obtained the day prior to surgery and no longer than 1 week prior to surgery. On two separate occasions, each patient's preoperative MR image was examined by two investigators who had no knowledge of the pathological diagnosis or results of VEG/PF staining. The method of reporting edema (PVBE) in this study involves initial measurement of the greatest anteroposterior and lateral dimensions of the tumor on axial contrast-enhanced T 1 -weighted slices. That area is in turn multiplied by the greatest tumor height on coronal or sagittal views to obtain an estimate of tumor volume. The same method was used for edema seen on the T 2 -weighted images. Because vasogenic edema emanates from the tumor vasculature and infiltrates into the surrounding white matter interstitial space, the peritumoral edema volume would be expected to include the tumor volume. Therefore when the edema volume is divided by the tumor volume, a ratio we call the edema index is generated. Using this method, a result of 1.0 implies the absence of peritumoral edema, whereas the presence of any edema will yield edema index values greater than 1.0. The edema indices for all of our specimens are reported in our Results section. As tumor shape and edema distribution more closely approximate spherical configurations, this rectilinear (length ϫ width ϫ height = volume) method of quantitating edema and tumor volumes would tend to overestimate both values. Nevertheless, its utility is retained for estimating the relative extent of PVBE associated with these lesions. The TACs were measured as though the cyst was part of the tumor and reported as present or not. If the fluid-filled cyst and tumor nodule were not surrounded by T 2 -weighted high signal within the brain parenchyma, the edema index was reported as 1.0/TAC (that is, no apparent PVBE, but present TAC). Tumorassociated cysts were therefore reported as a pathophysiologically related but morphologically distinct epiphenomenon of microvascular leakage.
Immunostaining for VEG/PF
Pathological specimens were cut from stored paraffinized samples and mounted on standard glass slides. Deparaffinization was achieved by treatment in xylene for 15 minutes. Endogenous peroxidase activity was quenched by exposing the slides to 3% hydrogen peroxide in methanol for 30 minutes. After rinsing three times (5 minutes per rinse) with phosphate-buffered saline (PBS) at pH 7.5, with gentle stirring throughout, the deparaffinized tissue was blocked with 3% bovine serum albumin (BSA) for 30 minutes. The slides were again rinsed in a PBS bath three times for a total of 15 minutes. Preimmune rabbit IgG, or a previously defined primary polyclonal anti-VEG/PF IgG, 6 was then added to a PBS solution containing 1% BSA and 0.1% Tween 20 detergent at a previously determined optimum dilution of 1:800 and allowed to incubate at room temperature for 1 hour. The slides were rinsed three times in PBS for 15 minutes. Subsequent steps were performed with a Vectastain Elite ABC and DAB chromogen kits according to manufacturer's instructions (Vector Laboratories, Inc., Burlingame, CA). To facilitate cytoplasmic visualization of the immunostained product, the slides were stained with hematoxylin for nuclear visualization while omitting cytoplasmic staining with eosin. The completed slides were then mounted and examined microscopically. Immunostaining results were correlated with tumor type and brain edema. Control experiments were performed on all specimens at the time of VEG/PF staining using normal rabbit serum. Experiments and control experiments were performed twice, on different days, using the same protocol and time exposures. Microscopic examination of all slides was conducted by two investigators who examined each specimen under ϫ 200 and ϫ 400 magnification. Slides were viewed simultaneously and without prior knowledge of final pathological diagnosis or MR imaging results. Agreement was reached on a slide-by-slide basis as to whether the tissue exhibited positive VEG/PF expression. Representative specimens were then photographed using an Olympus BH2 microscopy/microphotography system (Melville, NY) with Kodak Iso 160 Tungsten Ektachrome slide film (Eastman Kodak, Rochester, NY). Slide transparencies and cibachrome prints were produced to enhance the visual clarity and color quality of the final prints.
Results
Tumor neuropathological diagnosis/grade, VEG/PF expression, the extent (edema index) and presence of PVBE, presence or absence of TACs, and enhancement on MR imaging are presented in Table 1 . Staining for VEG/PF was reported as either present or absent. All VEG/PF immunoreactivity appeared concentrated on the cellular membranes or the surrounding interstitium in which microvessels are most clearly distinguished. Hypercellular tumors with a high nuclear-to-cytoplasmic ratio generally exhibited less staining in highly cellular areas and more staining in less cellular parts of the tumor interstitium. Three tumors exhibited distinct perivascular staining, although the endothelial cells themselves did not appear to be directly stained. Eight specimens that failed to stain for VEG/PF were identified as gliosis (four specimens), a hamartoma, a ganglioglioma, an oligodendroglioma, and an anaplastic astrocytoma. Of 26 tumors that expressed VEG/PF, 16 were low grade and 10 were high grade. Of the 18 low-grade tumors in this study, only two failed to express VEG/PF, whereas the remaining 16 im-munostained positively. All nine low-grade tumors exhibiting TACs immunostained positively for VEG/PF ( Figs. 1 and 2 ). Seven solid low-grade tumors exhibited extensive PVBE and VEG/PF expression (Fig. 3 ). In the high-grade tumor group, 10 of the 11 exhibited VEG/PF positivity and extensive PVBE (Fig. 4) . One Grade IV astrocytoma occurring in a 5-year-old child was associated with extensive PVBE and TAC formation (Fig. 5) . The VEG/PF-negative high-grade tumor was a medial temporal lobe anaplastic astrocytoma in a 29-year-old with minimal edema on MR imaging. Thus, VEG/PF expression does not appear to correlate with the tumor grade. This very definite association between VEG/PF expression and PVBE or TAC, and lack of association between tumor grade and VEG/PF expression, or tumor grade and edemagenesis or cyst formation is emphasized by the data summary presented in Table 2 .
The PVBE was quantitated and reported as an edema index, with 1.0 signifying no edema and values greater than 1.0 indicating progressively more edema. The magnitude of the edema index did not necessarily correlate with the location, uniformity, or intensity of VEG/PF staining. It is most notable that all 10 tumors associated with large cysts stained positively for VEG/PF, despite the absence of significant peritumoral white matter edema. In the present study, the degree of gadolinium enhancement appeared to correlate to some extent with tumor grade in that all 12 high-grade lesions demonstrated significant enhancement, whereas nine nonenhancing specimens were identified as gliosis or low-grade tumors. Notably however, nine low-grade lesions that enhanced brightly with gadolinium also immunostained positively for VEG/PF. These findings support previously reported observations on the consistent occurrence of neovascularity and blood-brain barrier disruption in malignant tumors. It has also been noted that certain benign CNS tumors (lowgrade astrocytomas, hemangioblastomas, and meningiomas) may also exhibit contrast enhancement PVBE and TAC formation. Therefore, these data indicate that the strongest correlation does not appear between tumor grade and contrast enhancement or tumor grade and VEG/PF expression per se, but is rather a correlation between the occurrence of edemagenesis, cyst formation, neovascularization or tumor enhancement, and the expression of the VEG/PF, irrespective or tumor type or grade.
Discussion
In recent years, the biochemical features and physiological behavior of a family of proteinaceous PFs (VEG/PFs) has received intense scrutiny. The existence of a VPF was initially reported in a study of the ascites fluid secreted by a guinea pig hepatocarcinoma. 38 Connolly and coworkers 6, 7 identified and purified VPF from a histiocytic lymphoma cell clone (U-937) VEGF while concurrently, another factor termed vascular endothelial growth factor (VEGF) was isolated from pituitary folliculostellate cells. 15, 21 Deoxyribonucleic acid sequencing of VPF and VEGF has revealed that these factors are essentially identical. 30, 36, 37, 44 Molecularly, VEG/PF is approximately a 40-to 45-kD heparin-binding glycoprotein with two apparently identical chains held together by disulfide bonds. 15, 18 Thus far it appears that several types of human VEG/PF have been isolated. In addition to the h-VPF isolated by Connolly and colleagues a cDNA library has yielded four isoforms to date. Three cDNA clones from the HL-60 lymphoma line, 30 and another clone from a fetal liver library, have been identified to date. 23 The four mature forms vary in size from 121 to 206 amino acids (VEG/PF 121 , VEG/PF 165 , VEG/PF 189 , and VEG/PF 206 ) and are likely encoded through analogous alternative exon splicing of messenger (m)RNA, rather than being encoded by distinct VEG/PF. 45 There is some evidence that VEG/PF 165 may be the most abundant. All VPF forms contain an N-terminal sequence consisting of a signaling motif for extracellular secretion and direction to a target structure in the interstitium.
Several studies have attested to VEG/PF's heparinbinding affinity, which proved instrumental in its early purification. 9, 39 It has been hypothesized that this heparin affinity is of physiological import, because the glycocalyx of vascular endothelial cells expresses abundant heparinlike moieties. Moreover, it was shown that coinjection of VPF with heparinase inhibited VPF activity in the Miles assay. This was thought to relate to interference or digestion of cell-surface VPF bindings sites. [10] [11] [12] This hypothesis is further supported by the finding that heparin strongly potentiates the formation of VPF receptor complexes on endothelial cells, as determined by cross-linking experiments. 19 All types of VEG/PFs discovered to date induce extravasation of Evans blue dye in the Miles assay. 33 In addition, all are able to specifically promote growth of endothelial cells in culture with half-maximal stimulation occurring at 2 to 3 pM. Recently, the VEG/PF receptor has been isolated and appears to be a high-affinity fms-like tyrosine kinase transmembrane receptor encoded by the flt-1 gene, 14 although it is unclear if this is the only receptor involved. The distribution of binding sites throughout the body has been examined and found to be highest in the brain, spinal cord, adrenal cortex, and lung. 26 Interestingly, within the brain there is particularly high binding in the pituitary pars distalis and nervosa, which are the most richly vascularized portions of the adenohypophysis. 16 A second tyrosine kinase receptor was cloned from human endothelial cells and designated kinase insert domain-con- * VEG/PF = vascular endothelial growth/permeability factor; PVBE = peritumoral vasogenic brain edema; TAC = tumor-associated cyst.
taining receptor. 42 More recently it was found that kinase insert domain-containing receptor encodes for a second VEG/PF receptor 34, 43 and that both receptors are expressed in human microvessel and large vessel endothelial cells. 1 Studies have demonstrated the potent permeabilityinducing activity of VEG/PF obtained from glioma-conditioned media and malignant cyst fluid. 2, 11, 12, 38 The VEG/PF gene has also been shown to be upregulated in glioblastoma multiforme cells, 35 and VEG/PF secretion appears to be inducible by stimulation of the epidermal growth factor receptor in glioblastoma multiforme specimens. 20 Furthermore, the high-affinity tyrosine kinase VEG/PF receptor (flt-1) was found to be upregulated in brain tumor endothelial cells with no apparent expression exhibited by normal brain microvascular endothelial cells. 35 The important role played by VEG/PF in tumor angiogenesis was highlighted by a study that demonstrated that blocking of VEG/PF activity in tumors implanted into nude mice significantly inhibited tumor growth. 28 Knowledge of the VEG/PF-induced cellular responses once receptor binding occurs is limited. A variety of cultured endothelial cells has been shown to undergo a rapid (Ͻ 60 second) and reversible induction of cytosolic calcium following VPF stimulation. 9 There also appears to be a rapid induction of inositol 1,4,5 triphosphate, suggesting that a second messenger involving inositol lipid hydrolysis may be involved. 17 As indicated in this discussion, VEG/PFs have been isolated from a variety of tumors. 12 A human glioma VPF was first detected in serum-free conditioned media of primary malignant human brain tumors (anaplastic astrocytomas and glioblastomas) by inducing microvascular extravasation in the Miles permeability bioassay. 4 The same change in permeability was not induced by conditioned media derived from low-grade astrocytomas or meningiomas. Furthermore, fluid aspirated from a cystic glioblastoma multiforme was shown to have a very intense permeability-inducing activity, whereas no such activity was noted with cerebrospinal fluid from normal volunteers. 4 Of significance, dexamethasone was shown to inhibit human glioma VPF expression in vitro, an effect that was specific and not associated with an inhibition of cellular protein synthesis. 12 This in vitro evidence has led us to investigate the presence of VPF in pathological specimens of human brain tumors and to correlate the findings with presence or absence of PVBE and TACs.
The current study supports the in vitro experiments and raises several new issues. Results of this investigation suggest that tumor grade in itself does not necessarily correlate with presence or absence of VEG/PF expression. Of the eight specimens negative for VEG/PF, four were samples of gliotic brain. The other four included a hamartoma, an oligodendroglioma, a ganglioglioma, and an anaplastic astrocytoma. None of these specimens had MR-documented PVBE or TAC formation. The occurrence of PVBE or TACs correlated very well, however, with presence of VEG/PF expression. To include TACs as a form of edema or more accurately, an epiphenomenon of microvascular extravasation, is a relatively new concept that has been recently reviewed 8 and warrants further consideration. Unlike nonneoplastic intracranial cysts such as arachnoid or leptomeningeal cysts that contain mainly cerebrospinal fluid, TACs have a large number of endogenous cerebral as well as plasma-derived proteins in their fluid. Among the endogenous cerebral proteins present are glial fibrillary acidic protein, S-100 protein, and ␤-endorphin. 22, 41, 46 However, it appears that these endogenous proteins represent a minority and that more than 92% of tumor cystic fluid protein is plasma derived. 31 The implication of this study is that an increase in the permeability of the blood-brain barrier takes place, allowing passage of plasma proteins into the cystic fluid. Furthermore, an electron microscopy examination of a cystic Grade II to III glioma revealed endothelial fenestrations in the capillaries lining the TAC identical to those present in patients with PVBE associated with solid tumors. 31 This fact strongly suggests that both PVBE and TACs share a common pathway at the endothelial cell level and that they may indeed represent dramatically distinct morphological expressions of the same pathophysiological process. All nine of our cystic lesions were associated with VEG/PF staining, regardless of tumor grade. We believe that these data support the view that benign and malignant TAC and PVBE share a common pathophysiology involving VEG/PF, angiogenesis, and microvascular extravasation.
Several types of VPF/VEGFs have been isolated, each with somewhat different dynamics. For instance, of the four types of VEGFs isolated from a human cDNA library, two (VEGF 189 and VEGF 206 ) were found to exhibit significantly more potency in inducing permeability in the Miles assay although demonstrating a markedly reduced mitogenic activity in comparison to the other isoforms. 23 In specimens reviewed for this report, the finding that permeability and morphological changes predominate may have been determined by the type of VEG/PF expressed.
There are several methodological issues regarding this study that need to be addressed. Although qualitatively we had no difficulty in determining whether edema was present or not, our attempt to quantitate the degree of edema and correlate that with the intensity of staining was limited. We recognize that the method of calculating edema index overestimates the volumes involved for both tumor and edema. By measuring dimensions at right angles to each other we simplified our task and provided a qualitative schema of reporting edema. However, the reported rectilinear volumes only approximate the relative extent of edema and do not precisely represent the actual volumes involved. This is partly because tumors and edema tend to be spherical in volume and thus smaller. Furthermore, because of the infiltrating nature of gliomas, their boundaries were at times approximated. Nevertheless, the ready visibility of water content on T 2 -weighted MR images allowed the presence of PVBE or TAC to be easily identified without question. The utility of the edema index derives from its ability to illustrate relative differences between the groups of tumors. Our VEG/PF negative group had an edema index of 1.0 (that is, no significant vasogenic edema). There was a highly statistically significant difference between the VEG/PF-positive and VEG/PF-negative groups. We can infer from the data that tumors exhibiting PVBE or TAC formation appears consistently to express VEG/PF.
We initially considered reporting intensity of VEG/PF as 1+ and 2+; however, we recognize that this intensity may vary not only with the amount of VEG/PF present but also with artifactual events such as location of specimen within a tumor, preparation, slide thickness, paraffiniza-tion, and variability in chromogen staining. Thus, in this study the absolute presence or absence of VPF proved more reliable and useful than the relative degree of staining.
Dexamethasone has been previously shown to inhibit the expression of human glioma VPF in vitro. In vivo animal experiments showed that coinjection or immediate preinjection treatment of animals with glucocorticoids did not confer protection from human glioma VPF-induced extravasation. However, 2-hour pretreatment with dexamethasone resulted in significant reduction but not abolition of the permeability-inducing effects of human glioma. 4 The majority of our patients received dexamethasone prior to excision of the specimen. Although symptoms related to mass effect and edema improved predictably in most patients, we are unable to comment with accuracy on the effect of steroid pretreatment on VEG/PF expression in vivo. The fundamental conclusion remains that patients with edema expressed VEG/PF regardless of whether dexamethasone was given. The possibility exists that VEG/ PF expression was diminished, as suggested by the in vitro studies, but this cannot be corroborated by our current data. However, it is entirely possible that dexamethasone may act in vivo by inhibiting the actions of VEG/PF at the microvascular endothelial cell level and not at the level of VEG/PF expression. In vitro studies examining VEG/PFinduced calcium transients in endothelial cells support this alternative hypothesis. 
Conclusions
This study reports a high correlation between the presence of VEG/PF in primary brain tumors and the occurrence of PVBE or TACs and tumor enhancement/vascularity, irrespective of tumor grade. These findings lend further compelling support for the hypothetical role of VEG/PF in the genesis of these epiphenomena of microvascular extravasation and in tumor angiogenesis.
